Poster Session A

9:45 AM

Breast Cancer

10:05 AM

The BCL2 antagonist of cell death (BAD) signaling pathway and phospho-BAD protein levels are associated with triple-negative breast cancer clinical development and clinical outcome

D. Marchion¹, Y. Xiong¹, R. Ismail-Khan¹, F. Abbasi¹, N. Bou Zgheib², I. Ramirez², S. H. Bush², A. Hakam¹, P. L. Judson Lancaster¹ and J. M. Lancaster¹
¹H. Lee Moffitt Cancer Center, Tampa, FL, ²University of South Florida College of Medicine, Tampa, FL

10:25 AM

Cervical Cancer

10:45 AM

147 - Poster Session A

Analysis of the effect of adjuvant radiotherapy on outcome and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors

K. Nakamura¹, T. Satoh¹, Y. Takei¹, S. Nagao², I. Sekiguchi¹ and M. Suzuki¹
¹Gynecologic Oncology Trial and Investigation Consortium of North Kanto, Japan, Iruma, Japan, ²Hyogo Cancer Center, Akashi, Hyogo, Japan

11:05 AM

148 - Poster Session A

The impact of multiple high-risk factors on survival outcome of surgically treated early-stage cervical cancer

K. Matsuo¹, S. Mabuchi², M. Okazawa², Y. Matsumoto³, K. Yoshino², S. Kamiura⁴, Y. G. Lin⁵, L. D. Roman⁶ and T. Kimura²
¹USC/LAC Medical Center - Women and Children’s Hospital, Los Angeles, CA, ²Osaka University, Suita, Japan, ³Osaka University, Osaka, Japan, ⁴Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan, ⁵University of Southern California, Los Angeles, CA, ⁶LAC+USC Medical Center - Women and Children’s Hospital, Los Angeles, CA

11:25 AM

149 - Poster Session A

Cervical adenocarcinoma in situ with coexisting squamous cell lesions: impact on recurrence

T. Song¹, B. S. Yoon¹, Y. Y. Lee², C. H. Choi², T. J. Kim³, J. W. Lee³, D. S. Bae³, B. G. Kim³ and M. K. Kim⁴
¹CHA Gangnam Medical Center, CHA University, Seoul, South Korea, ²Samsung Medical Center, Seoul, South Korea, ³Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Sungkyunkwan University School of Medicine, Changwon-Si, South Korea

11:45 AM

150 - Poster Session A

N. Thomakos, M. Sotiropoulou, D. Zacharakis, I. Koutroumpa, E. Valla, S. P. Trachana, D. Haidopoulos, F. Zagouri, G. Vlachos and A. Rodolakis
Alexandra Hospital, University of Athens, Athens, Greece

12:05 PM

151 - Poster Session A

Differentiation between high- and low-grade cervical intraepithelial neoplasia by p16 imunnoexpression

C. E. M. D. C. Andrade¹, M. A. Vieira¹, R. Dos Reis¹, A. T. Tsunoda¹, A. Longatto-Filho¹, C. Scapulatempo-Neto², I. D. C. G. Da Silva¹ and J. T. G. Fregnani²
¹Barretos Cancer Hospital, Barretos, Brazil, ²Hospital de Câncer de Barretos, Barretos, Brazil

12:25 PM

152 - Poster Session A

Risk factors for cervical intraepithelial neoplasia (CIN) recurrence in patients with positive cone margins

C. E. M. D. C. Andrade¹, R. Dos Reis¹, M. A. Vieira¹, I. D. C. G. Da Silva¹, A. T. Tsunoda¹, J. T. G. Fregnani² and F. A. Soares³
¹Barretos Cancer Hospital, Barretos, Brazil, ²Hospital de Câncer de Barretos, Barretos, Brazil, ³AC Camargo Cancer Center, Sao Paulo, Brazil

12:45 PM

153 - Poster Session A

The diagnostic utility of HR-HPV as a predictor of cervical cancer recurrence

M. C. Yu¹, R. M. Austin¹, J. F. Lin¹, T. L. Beck², S. Beriwal¹, J. T. Comerci¹, R. P. Edwards¹, P. Sukumvanich¹, J. L. Kelley III¹ and A. B. Olawaiye¹
¹Magee-Womens Hospital of UPMC, Pittsburgh, PA, ²University of Washington Medical Center, Seattle, WA

1:05 PM

154 - Poster Session A

Synaptonemal complex protein 3 is a prognostic marker in cervical cancer

H. Cho¹, S. Kim¹, D. B. Chay¹, Y. T. Kim¹ and J. H. Kim²
¹Yonsei University College of Medicine, Seoul, South Korea, ²Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

1:25 PM

155 - Poster Session A

MICA/B and ULBP1 natural killer group 2 member D (NKG2D) ligands are independent predictors of prognosis in cervical cancer

H. Cho¹, D. B. Chay¹, S. Kim¹, Y. T. Kim¹ and J. H. Kim²
¹Yonsei University College of Medicine, Seoul, South Korea, ²Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

1:45 PM

156 - Poster Session A

Impact of treatment time on chemoradiotherapy in locally advanced cervical carcinoma

S. Pathy, L. Kumar, R. M. Pandey, V. Dadhwal, S. Chander and R. Madan
All India Institute of Medical Sciences, New Delhi, India

2:05 PM

157 - Poster Session A

Makorin ring finger protein 1 (MKRN1) as an adjunct marker in liquid-based cervical cytology

M. Y. Chang¹, S. Kim², H. Cho², D. B. Chay², Y. T. Kim² and J. H. Kim¹
¹Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, South Korea

2:25 PM

158 - Poster Session A

High rates of cervical intraepithelial neoplasia (CIN) 3 in young women undergoing immediate excisional procedure for high-grade squamous intraepithelial lesion (HSIL) cytology

H. J. Smith, B. K. Erickson, L. R. Daily, A. V. Glover, E. E. Landers, D. N. Pasko, M. L. Plash, L. B. Johnston, C. A. Leath III and W. K. Huh
University of Alabama at Birmingham, Birmingham, AL

2:45 PM

159 - Poster Session A

Fertility-sparing surgery after high dose-dense neoadjuvant chemotherapy: critical view of experiences with 25 patients

H. Robova¹, L. Rob¹, M. Pluta¹, M. J. Halaska¹, J. Matecha² and P. Skapa¹
¹Charles University in Prague, Prague 5, Czech Republic, ²Hospital Motol, Prague 5, Czech Republic

3:05 PM

160 - Poster Session A

Efficacy of adjuvant chemotherapy after radical hysterectomy in FIGO stage IB-IIA cervical cancer: Comparison with adjuvant RT/CCRT using Propensity Scores

D. Y. Kim, P. S. Jung, S. W. Lee, J. Y. Park, D. S. Suh, J. H. Kim, Y. M. Kim, Y. T. Kim and J. H. Nam
University of Ulsan College of Medicine, ASAN Medical Center, Seoul, South Korea

3:25 PM

161 - Poster Session A

Less radical surgery than radical trachelectomy or radical hysterectomy in patients with stage I cervical cancer

L. Rob¹, H. Robova¹, M. Pluta¹, M. J. Halaska¹, J. Matecha² and P. Skapa¹
¹Charles University in Prague, Prague 5, Czech Republic, ²Hospital Motol, Prague 5, Czech Republic

3:45 PM

162 - Poster Session A

A study of safe criteria for radical trachelectomy in cervical cancer patients to prevent recurrence and catastrophic consequences: a multicenter study

D. Kim¹, S. J. Chang², T. W. Kong², J. H. Kim¹, Y. M. Kim¹, Y. T. Kim¹, H. S. Ryu³ and J. H. Nam¹
¹University of Ulsan College of Medicine, ASAN Medical Center, Seoul, South Korea, ²Ajou University Hospital, Suwon, South Korea, ³Ajou University School of Medicine, Suwon, South Korea

4:05 PM

163 - Poster Session A

Less radical surgery for early-stage cervical cancer: can cold knife cone specimens help identify those at low risk for parametrial involvement?

G. A. L. McCann¹, B. Smith², G. Phillips² and R. Salani²
¹University of Texas Health Science Center at San Antonio, San Antonio, TX, ²The Ohio State University, Columbus, OH

4:25 PM

164 - Poster Session A

Adenocarcinoma indicates more favorable prognosis with cervix cancer

C. C. Gunderson¹, A. Walter², S. Vesely¹, E. D. Thomas³, A. Park⁴, L. Perry¹, D. S. McMeekin¹ and K. N. Moore¹
¹The University of Oklahoma, Oklahoma City, OK, ²The University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK, ³Stephenson Cancer Center, The University of Oklahoma, Oklahoma City, OK, ⁴The University of Oklahoma Health Sciences Center, Oklahoma City, OK

4:45 PM

165 - Poster Session A

Diagnosis of adenocarcinoma in situ (AIS): changing trends and the impact of human papillomavirus (HPV) testing

A. I. Tergas^1,2, E. George², J. D. Wright², X. Chen¹ and T. C. Wright¹
¹Columbia University College of Physicians and Surgeons, New York, NY, ²Columbia University, New York, NY

5:05 PM

166 - Poster Session A

Prognostic role of maximum standardized uptake value of metastatic pelvic lymph node in patients with early-stage cervical cancer for the prediction of distant metastasis

J. H. Hong¹, J. W. Kim², J. Y. Song³, S. Kim¹, J. K. Lee¹ and N. W. Lee⁴
¹Guro Hospital, Korea University College of Medicine, Seoul, South Korea, ²Ansan Hospital, Korea University College of Medicine, Ansan, South Korea, ³Korea University College of Medicine, Seoul, South Korea, ⁴Ansan Hospital Korea University College of Medicine, Ansan, South Korea

5:25 PM

Chemotherapy

5:45 PM

167 - Poster Session A

Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: an institutional experience

D. M. Roque, C. L. Schwab, D. P. English, E. S. Ratner, D. A. Silasi, M. Azodi, T. J. Rutherford, P. E. Schwartz and A. Santin
Yale University School of Medicine, New Haven, CT

6:05 PM

168 - Poster Session A

A dose-dense paclitaxel and carboplatin regimen is highly active in the treatment of recurrent and advanced endometrial cancer

J. Hunn^1,2, M. E. Tenney¹, A. Puglisi², E. S. Diaz², G. L. Maxwell³, C. V. Kirschner², J. A. Hurteau^1,2 and G. C. Rodriguez^1,2
¹University of Chicago, Chicago, IL, ²Northshore University Health System, Evanston, IL, ³Inova Fairfax Hospital, Falls Church, VA

6:25 PM

169 - Poster Session A

Oxaliplatin is a safe alternative therapeutic option for patients with recurrent gynecologic cancers following hypersensitivity reaction to carboplatin

N. V. Kolomeyevskaya¹, A. Miller¹, G. Riebandt¹, B. Blum¹, K. Hacker², S. N. Akers¹, K. O. Odunsi¹, S. B. Lele¹ and P. J. Frederick¹
¹Roswell Park Cancer Institute, Buffalo, NY, ²Syracuse VA Medical Center, Syracuse, NY

6:45 PM

170 - Poster Session A

Distribution of ovarian cancer recurrence following intravenous (IV) and intraperitoneal (IP) adjuvant chemotherapy after upfront cytoreductive surgery

R. Vargas¹, J. A. Rauh-Hain², K. M. Esselen³, N. S. Horowitz⁴, J. O. Schorge², M. G. Del Carmen², S. M. Campos⁵ and W. B. Growdon⁶
¹Massachusetts General Hospital/Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital/Harvard University, Boston, MA, ³Brigham and Women's Hospital/Harvard University, Boston, MA, ⁴Harvard University, Boston, MA, ⁵Dana Farber Cancer Center, Boston, MA, ⁶Massachusetts General Hospital, Boston, MA

7:05 PM

171 - Poster Session A

A dose a day keeps the cancer away: metronomic albumin-bound paclitaxel and topotecan has potent antitumor activity in ovarian cancer

A. N. Davis¹, Y. G. Lin², R. A. Previs¹, H. J. Dalton¹, R. L. Stone³, J. N. Bottsford-Miller¹, B. Zand¹, R. L. Coleman¹, A. K. Sood¹ and M. Taylor¹
¹The University of Texas MD Anderson Cancer Center, Houston, TX, ²University of Southern California, Los Angeles, CA, ³University of Arkansas for Medical Sciences, Little Rock, AR

7:25 PM

172 - Poster Session A

Nanoparticle albumin-bound (nab) paclitaxel therapy in patients with primary and recurrent ovarian, fallopian tube, and primary peritoneal carcinoma

N. Rasool¹, S. Talukdar², Y. Wang¹, R. K. Hanna¹, T. E. Buekers¹, A. R. Munkarah¹ and S. Hensley Alford¹
¹Henry Ford Health System, Detroit, MI, ²Henry Ford Health Systems, Detroit, MI

7:45 PM

173 - Poster Session A

Serum antibodies recognizing hypoxia-inducible factor 1-alpha and platinum sensitivity in ovarian cancer

M. D. Dao¹, K. J. Agnew¹, E. M. Swisher¹, B. A. Goff¹, M. L. Disis² and J. B. Liao²
¹University of Washington Medical Center, Seattle, WA, ²University of Washington, Seattle, WA

8:05 PM

174 - Poster Session A

Is it equivalent?: a comparison of the clinical activity of Lipodox compared to Doxil in the treatment of recurrent ovarian cancer

J. A. Smith¹, A. B. Costales², M. Jaffari¹, D. Urbauer¹, M. Frumovitz¹, C. K. Kutac¹, H. Tran¹ and R. L. Coleman¹
¹The University of Texas MD Anderson Cancer Center, Houston, TX, ²The University of Texas Medical School at Houston, Houston, TX

8:25 PM

Clinical Practice Issues

8:45 PM

175 - Poster Session A

Semi-quantitative human papillomavirus virus (HPV) viral load correlates with the presence and grade of preneoplastic lesions of the uterine cervix in patients with atypical squamous cells of undetermined significance (ASCUS) cytology

S. J. Lee
Konkuk University School of Medicine, Seoul, South Korea

9:05 PM

176 - Poster Session A

Narrative medicine: using reflective writing workshops to help house staff address the complex and challenging nature of caring for gynecologic oncology patients

H. A. Moss¹, A. F. Winkel¹, A. Jewell², F. Musa¹, L. Mitchell¹, E. Speed¹ and S. V. Blank¹
¹New York University School of Medicine, New York, NY, ²University of Chicago, Chicago, IL

9:25 PM

177 - Poster Session A

Evaluating an adnexal mass using a multivariate index assay and imaging

S. Goodrich¹, R. E. Bristow², J. T. Santoso³, C. P. Desimone⁴, R. W. Miller⁴, A. Smith⁵, J. R. Vannagell⁴, Z. Zhang⁶ and F. R. Ueland⁴
¹United States Army Medical Command, Tacoma, WA, ²University of California, Irvine, Irvine, CA, ³University of Tennessee West Clinic, Memphis, TN, ⁴University of Kentucky Medical Center, Lexington, KY, ⁵Applied Clinical Intelligence, Bala Cynwyd, PA, ⁶Johns Hopkins Medical Institutions, Baltimore, MD

9:45 PM

178 - Poster Session A

Is hysterectomy safe after concurrent radiochemotherapy of cervical cancer?

Y. Gao
Beijing Cancer Hospital, Beijing, China

10:05 PM

179 - Poster Session A

Determinants of pelvic and para-aortic lymph node metastasis in endometrial cancer and its role in tailoring lymphadenectomy

H. Fakhry¹ and I. Konishi²
¹South Egypt Cancer Institute, Assiut University, Assiut, Egypt, ²Kyoto University Graduate School of Medicine, Sakyo-ku, Japan

10:25 PM

180 - Poster Session A

Perioperative thromboembolism prophylaxis: how much is enough?

E. Chalas¹, M. Quinones¹, V. Rojas¹, J. A. Villella¹, K. C. Chan¹, E. A. Jimenez¹ and S. Islam²
¹Winthrop University Hospital, Mineola, NY, ²WInthrop University Hopital, Mineola, NY

10:45 PM

181 - Poster Session A

Malignant endometrial polyps in uterine serous carcinoma: does size matter?

C. Ouyang¹, M. Frimer¹, Y. Wang¹, L. Y. Hou², D. Y. S. Kuo¹, G. L. Goldberg¹ and J. Y. Hou¹
¹Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²New England Baptist Hospital, Boston, MA

11:05 PM

182 - Poster Session A

Trends in patient care after discontinuation of daily progress checklists after transition to electronic patient documentation: evaluation of prophylactic compliance and surgical outcomes among gynecologic oncology patients

L. P. Cobb¹, M. Gerardi Fairbairn², R. L. Giuntoli II³ and T. P. Diaz-Montes⁴
¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Medical Institutions, Columbia, MD, ³Johns Hopkins Medical Institutions, Baltimore, MD, ⁴Mercy Medical Center, Owings Mills, MD

11:25 PM

183 - Poster Session A

Preoperative hypoalbuminemia is a risk factor for 30-day morbidity after gynecologic malignancy surgery

S. H. Shim, J. Kim, J. E. Kim, J. Y. Im, S. H. Yun, S. J. Lee, S. N. Kim and S. B. Kang
Konkuk University School of Medicine, Seoul, South Korea

11:45 PM

184 - Poster Session A

Factors associated with clinical trial screening failures in gynecologic oncology

D. B. Manders¹, A. Paulsen¹, D. L. Richardson¹, S. M. Kehoe¹, D. S. Miller² and J. S. Lea¹
¹University of Texas Southwestern Medical Center, Dallas, TX, ²The University of Texas Southwestern Medical Center, Dallas, TX

12:05 AM

185 - Poster Session A

Prediction model for 30-day morbidity after gynecologic malignancy surgery

S. H. Shim, J. Kim, S. H. Yun, S. J. Lee, S. N. Kim and S. B. Kang
Konkuk University School of Medicine, Seoul, South Korea

12:25 AM

186 - Poster Session A

Gynecologic oncology fellow perspectives on research and career development symposia: a Gynecologic Oncology Fellows' and Allied Health Professionals' Research Network (GOFRN) survey study

E. L. Dickson¹, J. F. Lin², A. I. Tergas³, R. N. Eskander⁴, J. J. Mueller⁵, L. L. Holman⁶, R. E. Bristow⁷ and A. Nickles Fader⁸
¹University of Minnesota, Minneapolis, MN, ²Magee-Womens Hospital of UPMC, Pittsburgh, PA, ³Columbia University, New York, NY, ⁴University of California at Irvine Medical Center, Orange, CA, ⁵Memorial Sloan Kettering Cancer Center, New York, NY, ⁶The University of Texas MD Anderson Cancer Center, Houston, TX, ⁷University of California, Irvine, Irvine, CA, ⁸Johns Hopkins Medical Institutions, Baltimore, MD

12:45 AM

Hereditary Cancers & The Role of Genetics

1:05 AM

187 - Poster Session A

Assessment of primary care providers' current clinical practices in determining a woman's risk for ovarian cancer

B. Schlappe¹, A. Schwartz², C. Wong¹, R. Luebbers¹ and E. Everett¹
¹University of Vermont, Burlington, VT, ²University of Wisconsin, Madison, WI

1:25 AM

188 - Poster Session A

A new Lynch syndrome: what is the role for polymerase D1 mutations in hereditary endometrial cancer?

K. L. Ring, A. S. Bruegl, J. Celestino, R. E. Schmandt, R. Broaddus and K. H. Lu
The University of Texas MD Anderson Cancer Center, Houston, TX

1:45 AM

189 - Poster Session A

Prevalence and clinical predictors of germline PTEN mutation in endometrial cancer patients with Cowden and Cowden-like syndrome

H. Mahdi¹, J. L. Mester², C. Michener¹ and C. Eng²
¹Cleveland Clinic, Cleveland, OH, ²The Cleveland Clinic, Cleveland, OH

2:05 AM

190 - Poster Session A

Germline SDHB/C/D variation and KLLN promoter methylation in endometrial cancer patients with Cowden and Cowden-like syndrome

H. Mahdi¹, J. L. Mester², E. Nizialek², C. Michener¹ and C. Eng²
¹Cleveland Clinic, Cleveland, OH, ²The Cleveland Clinic, Cleveland, OH

2:25 AM

191 - Poster Session A

PD-0332991, a cyclin-dependent kinase 4/6 inhibitor, is an active agent in uterine cancer cells

J. A. Ducie¹, P. Jelinic¹, Z. Zhang², F. Dao¹, M. Bisogna¹, V. Makker² and D. A. Levine¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Memorial Sloan-Kettering Cancer Center, New York, NY

2:45 AM

192 - Poster Session A

Exome sequencing identifies germline mutations involving novel single nucleotide polymorphisms within DNA repair pathway genes in uterine serous carcinoma

M. Frimer¹, K. Levano², A. G. Rodriguez-Gabin³, C. Ouyang¹, J. Cai¹, Y. Wang¹, M. H. Einstein¹, G. L. Goldberg¹, S. B. Horwitz³ and J. Y. Hou¹
¹Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²Peruvian National Institute of Health, Lima 9, Peru, ³Albert Einstein College of Medicine, Bronx, NY

3:05 AM

193 - Poster Session A

Breast cancer risk with hormone replacement after risk-reducing Salpingo-oophorectomy in BRCA mutation carriers: does it abrogate the benefit?

J. N. Barlin¹, A. Arnold¹, S. Mobley¹, E. Otegbeye¹, Z. K. Stadler¹, M. E. Robson¹, K. Offit¹, R. R. Barakat² and N. D. Kauff²
¹Memorial Sloan-Kettering Cancer Center, New York, NY, ²Memorial Sloan Kettering Cancer Center, New York, NY

3:25 AM

194 - Poster Session A

A KRAS hot spot mutation correlates with MLH1 methylation in endometrial carcinomas with microsatellite instability: a potential triage tool for Lynch syndrome evaluation

J. G. Cohen¹, R. Wiedemeyer¹, B. Y. Karlan² and C. Walsh¹
¹Cedars-Sinai Medical Center, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA

3:45 AM

195 - Poster Session A

Genetic mutations and characteristics of “resistant” BRCA1 and BRCA2 carriers cohort

N. A. Latif and T. R. Rebbeck
University of Pennsylvania, Philadelphia, PA

4:05 AM

196 - Poster Session A

Gene expression profiles of high-grade serous ovarian cancers in patients with normal CA-125 levels at the time of recurrence

V. Broach, F. Dao and D. A. Levine
Memorial Sloan Kettering Cancer Center, New York, NY

4:25 AM

197 - Poster Session A

Association of in vitro chemotherapy drug resistance assays in ovarian cancer patients with BRCA1/2 mutations

J. Lee, A. W. Menzin, V. S. John, J. L. Lovecchio and J. S. Whyte
Hofstra - North Shore Long Island Jewish School of Medicine, Manhasset, NY

4:45 AM

Ovarian/Fallopian Tube/Primary Peritoneal Cancer

5:05 AM

198 - Poster Session A

Inhibition of chaperone-mediated autophagy may be a novel approach to increase platinum susceptibility in ovarian cancer cell lines

L. A. Spoozak¹, C. Park¹, M. R. Ewart¹, G. L. Goldberg² and A. M. Cuervo¹
¹Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

5:25 AM

199 - Poster Session A

The management of peritoneal surface malignancies: single-center initial experience

M. A. F. Seoud, F. Jamali, A. Shamesseddine and M. J. Khalifeh
American University of Beirut Medical Center, Beirut, Lebanon

5:45 AM

200 - Poster Session A

The mTOR inhibitor RAD001 exhibited more efficacy against ovarian cancer ascites after pharmacologic inhibition of Mirk kinase

X. Deng¹, J. Hu¹, M. J. Cunningham² and E. A. Friedman¹
¹Upstate Medical University, Syracuse, NY, ²GYN Oncology of CNY, PC, East Syracuse, NY

6:05 AM

201 - Poster Session A

The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass

L. R. Eiriksson¹, H. C. Millar², G. K. Lennox², C. J. M. Reade², F. Leung^2,3, E. P. Diamandis^2,3,4, V. Kulasingam^2,4, K. J. Murphy⁵, S. E. Ferguson⁵ and M. Q. Bernardini⁵
¹Juravinski Hospital and Cancer Centre, Hamilton Health Sciences, Hamilton, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵Princess Margaret Hospital, Toronto, ON, Canada

6:25 AM

202 - Poster Session A

Do high-grade stage I ovarian cancers benefit from adjuvant chemotherapy?

Y. Segev II¹, N. Ismiil¹, R. M. McVey² and A. L. Covens²
¹Sunnybrook Hospital and Health Sciences Center, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada

6:45 AM

203 - Poster Session A

Risk factors for progression to invasive carcinoma in patients with borderline ovarian tumors

T. Song¹, B. S. Yoon², Y. Y. Lee¹, C. H. Choi¹, T. J. Kim³, J. W. Lee³, D. S. Bae³ and B. G. Kim³
¹Samsung Medical Center, Seoul, South Korea, ²CHA Gangnam Medical Center, CHA University, Seoul, South Korea, ³Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

7:05 AM

204 - Poster Session A

Clinicopathological prognostic factors for recurrence in adult granulosa cell tumor of the ovary

I. Koutroumpa, N. Thomakos, M. Sotiropoulou, S. P. Trachana, D. Haidopoulos, F. Zagouri, C. Papadimitriou, G. Vlachos, A. Bamias and A. Rodolakis
Alexandra Hospital, University of Athens, Athens, Greece

7:25 AM

205 - Poster Session A

Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer

H. E. Dinkelspiel, L. D. Zimmerman, S. N. Lewin, A. I. Tergas, W. M. Burke, Y. S. Lu, T. J. Herzog and J. D. Wright
Columbia University, New York, NY

7:45 AM

206 - Poster Session A

Clinical response to anti-estrogen therapy in platinum-resistant ovarian cancer patients and the role of tumor estrogen receptor expression status

M. Stasenko, M. Plegue and K. McLean
University of Michigan Health Systems, Ann Arbor, MI

8:05 AM

207 - Poster Session A

Impact of lymphovascular space invasion (LVSI) on survival of stage I epithelial ovarian cancer

K. Matsuo¹, K. Yoshino², M. Nishimura³, K. Hiramatsu⁴, C. Banzai⁵, T. B. Sheridan⁶, K. Hasegawa⁷, Y. Shiki⁸, L. D. Roman⁹ and A. K. Sood¹⁰
¹USC/LAC Medical Center - Women and Children’s Hospital, Los Angeles, CA, ²Osaka University, Suita, Japan, ³University of Tokushima, Tokushima, Japan, ⁴Osaka University Graduate School of Medicine, Suita, Japan, ⁵Niigata University Graduate School of Medicine, Niigata, Japan, ⁶Mercy Medical Center, Baltimore, MD, ⁷Saitama Medical University International Medical Center, Saitama, Japan, ⁸Osaka Rosai Hospital, Sakai, Japan, ⁹LAC+USC Medical Center - Women and Children’s Hospital, Los Angeles, CA, ¹⁰The University of Texas MD Anderson Cancer Center, Houston, TX

8:25 AM

208 - Poster Session A

Preoperative predictors which impact the survival and outcome of secondary cytoreduction in ovarian cancer

M. Katsnelson, S. C. Rubin, W. T. Hwang and J. L. Tanyi
University of Pennsylvania, Philadelphia, PA

8:45 AM

209 - Poster Session A

Tumor microvessel density does not correlate with bevacizumab response in recurrent ovarian cancer

E. K. Hill¹, M. Steinhoff², C. Raker¹ and P. A. DiSilvestro¹
¹Women & Infants Hospital, Brown University, Providence, RI, ²Women and Infants Hospital, Brown University, Providence, RI

9:05 AM

210 - Poster Session A

Outcome and response to neoadjuvant chemotherapy in patients with advanced stage Müllerian cancer in BRCA1/2 mutation-positive compared to mutation-negative women

H. Mahdi¹, J. R. Woessner², M. E. Buechel², J. Moline², C. Eng², C. Michener¹ and P. G. Rose¹
¹Cleveland Clinic, Cleveland, OH, ²The Cleveland Clinic, Cleveland, OH

9:25 AM

211 - Poster Session A

MK-2206 sensitizes BRCA2 mutant ovarian adenocarcinoma to cisplatin and poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitor therapy

M. E. Whicker, Z. P. Lin, A. C. Sartorelli and E. S. Ratner
Yale University School of Medicine, New Haven, CT

9:45 AM

212 - Poster Session A

HNF1B contributes to resistance to oxidative stress through modification of metabolism in ovarian clear cell carcinoma

K. Yamaguchi¹, Y. Amano¹, N. Matsumura¹, M. Mandai², K. Abiko¹, J. Hamanishi¹, Y. Yoshioka¹, T. Baba¹ and I. Konishi¹
¹Kyoto University, Kyoto, Japan, ²Kinki University, Osakasayama, Japan

10:05 AM

213 - Poster Session A

Utility of serum folate-binding protein as a biomarker in the monitoring and treatment of ovarian cancer

I. Winer¹, S. Albayrak², N. Levin³, S. Khuder⁴, Q. F. Ahmed¹, R. Ali-Fehmi¹, R. T. Morris¹, M. A. Tainsky³ and M. Ratnam³
¹Wayne State University, Detroit, MI, ²Detroit Medical Center, Detroit, MI, ³Karmanos Cancer Institute, Detroit, MI, ⁴University of Toledo, Toledo, OH

10:25 AM

214 - Poster Session A

BCL2 antagonist of cell death (BAD) gene sequence and functional analysis of phosphorylation sites in ovarian cancer

N. Bou Zgheib¹, Y. Xiong², D. Marchion², I. Ramirez¹, S. H. Bush¹, P. L. Judson Lancaster², A. Hakam², R. M. Wenham², S. M. Apte² and J. M. Lancaster²
¹University of South Florida College of Medicine, Tampa, FL, ²H. Lee Moffitt Cancer Center, Tampa, FL

10:45 AM

215 - Poster Session A

Incidence of lymph node metastasis in comprehensively staged clear cell carcinoma grossly confined to the ovary

J. J. Mueller¹, C. H. Han², K. Santos³, S. Wethington³, S. Z. Dejbakhsh⁴, R. R. Barakat³, G. J. Gardner¹, D. Hyman¹, R. A. Soslow¹ and M. M. Leitao³
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Flushing Hospital Medical Center, Flushing, NY, ³Memorial Sloan-Kettering Cancer Center, New York, NY, ⁴Columbia University Mailman School of Public Health, New York, NY

11:05 AM

216 - Poster Session A

The role of secondary cytoreduction in patients with recurrent low-grade serous ovarian carcinoma

E. R. King, C. C. L. Sun, P. T. Ramirez, K. M. Schmeler, A. Malpica and D. M. Gershenson
The University of Texas MD Anderson Cancer Center, Houston, TX

11:25 AM

217 - Poster Session A

Significance of serum CA-125 level as a prognostic factor after the first cycle of chemotherapy in patients with advanced serous epithelial ovarian cancer

S. Kim¹, M. Y. Chang², D. B. Chay¹, H. Cho¹, Y. T. Kim¹ and J. H. Kim²
¹Yonsei University College of Medicine, Seoul, South Korea, ²Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

11:45 AM

218 - Poster Session A

The Charlson Comorbidity Index predicts survival in women with epithelial ovarian cancer independent of surgical debulking status

B. K. Erickson, T. Matin, J. Y. Martin, M. M. Shah, D. N. Pasko, C. L. Walters Haygood, L. R. Daily, M. Straughn and C. A. Leath III
University of Alabama at Birmingham, Birmingham, AL

12:05 PM

219 - Poster Session A

Targeting PI3K/AKT signaling and the TR3/NR4A1 receptor in ovarian cancer

A. Wilson, J. Saskowski, J. Garrett, C. Arteaga and D. Khabele
Vanderbilt University, Nashville, TN

12:25 PM

220 - Poster Session A

Forkhead box M1 (FOXM1) gene expression inversely correlates with survival and targeting FOXM1 improves cytotoxicity of paclitaxel and cisplatinum in platinum-resistant ovarian cancer ascites cells ex vivo

G. L. Westhoff¹, Y. Chen², M. Bieber² and N. N. H. Teng²
¹Stanford Hospital and Clinics, Stanford, CA, ²Stanford University Medical Center, Stanford, CA

12:45 PM

221 - Poster Session A

A mycobacterial heat shock protein 70-based fusion protein targeting mesothelin induces dendritic cell maturation and cross-presentation in a murine model of ovarian carcinoma

N. Hashim Arrifin^1,2, J. Yuan², S. Kashiwagi², M. Nguyen², G. Jean-Mary², J. Nezivar², Y. Yang², P. Leblanc², T. Brauns² and M. Poznansky²
¹Imperial College London, London, United Kingdom, ²Massachusetts General Hospital, Charlestown, MA

1:05 PM

222 - Poster Session A

Pelvic magnetic resonance imaging diagnosis correlates with pathology of adnexal masses

A. F. Haggerty¹, A. R. Hagemann², C. Chu¹, E. Siegelman³ and S. C. Rubin¹
¹University of Pennsylvania, Philadelphia, PA, ²Washington University School of Medicine, St. Louis, MO, ³University of Pennsylvania Health System, Philadelphia, PA

1:25 PM

223 - Poster Session A

The presence of endometriosis is associated with improved survival in epithelial ovarian cancer

H. E. Dinkelspiel, C. Matrai, S. Pauk, Y. L. Chiu, D. Gupta, T. A. Caputo, L. Ellenson and K. M. Holcomb
Weill Cornell Medical Center, New York, NY

1:45 PM

224 - Poster Session A

Characterization of primary platinum resistance in an era of biologic agents and novel chemotherapeutic design

E. D. Thomas¹, K. N. Slaughter², C. C. Gunderson², L. Perry², R. Farrell², J. K. Lauer³, K. Ding², D. S. McMeekin² and K. N. Moore²
¹Stephenson Cancer Center, The University of Oklahoma, Oklahoma City, OK, ²The University of Oklahoma, Oklahoma City, OK, ³The University of Oklahoma, okc, OK

2:05 PM

225 - Poster Session A

Primary debulking surgery in stage IIIC and IV ovarian cancer results in improved survival compared to those undergoing neoadjuvant chemotherapy with interval cytoreduction

R. M. Clark¹, J. T. Clemmer¹, A. Melamed², J. A. Rauh-Hain¹, N. Joseph¹, D. M. Boruta II¹, M. G. Del Carmen¹, A. Goodman¹, W. B. Growdon³ and J. O. Schorge¹
¹Massachusetts General Hospital/Harvard University, Boston, MA, ²Brigham and Women's Hospital/Massachussets General Hospital, Boston, MA, ³Massachusetts General Hospital, Boston, MA

2:25 PM

226 - Poster Session A

Hypomethylation signature enriches stem properties and predicts poor prognosis for ovarian cancer patients

Y. P. Liao^1,2 and H. C. Lai^1,2
¹National Defense Medical Center, Taipei, Taiwan, ²Tri-service General Hospital, Taipei, Taiwan

2:45 PM

227 - Poster Session A

Hyperthermic intraperitoneal chemotherapy in the treatment of ovarian, fallopian tube, and peritoneal cancer: an analysis of recurrence patterns and survival

J. Tseng¹, J. C. Cripe II², A. Nickles Fader¹, R. E. Bristow³ and E. J. Tanner III¹
¹Johns Hopkins Medical Institutions, Baltimore, MD, ²University of California at Irvine Medical Center, Orange, CA, ³University of California, Irvine, Irvine, CA

3:05 PM

228 - Poster Session A

A “REST-less” phenotype is associated with favorable recurrence-free survival in ovarian cancer

C. M. Niemi, J. Y. Lim, M. N. Moffitt, E. G. Munro and T. Pejovic
Oregon Health & Science University, Portland, OR

3:25 PM

229 - Poster Session A

Subcellular localization of AT-rich interactive domain1A protein expression is associated with survival in epithelial ovarian and peritoneal carcinoma

K. A. Byrd¹, G. L. Maxwell², W. Bshara³, J. I. Risinger⁴, C. Tian⁵, A. R. Omilian⁶, K. O. Odunsi³, C. Morrison³, T. P. Conrads⁷ and W. Consortium⁸
¹Naval Medical Center Portsmouth, Portsmouth, VA, ²Inova Fairfax Hospital, Falls Church, VA, ³Roswell Park Cancer Institute, Buffalo, NY, ⁴Michigan State University, Grand Rapids, MI, ⁵Precision Therapeutics, Inc., Pittsburgh, PA, ⁶Roswell Park Cancer Institute, buffalo, NY, ⁷Gynecologic Cancer Center of Excellence, Annandale, VA, ⁸Women's Health Integrated Research Center, Annandale, VA

3:45 PM

230 - Poster Session A

An analysis of short-term morbidity associated with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer

S. Singh¹, A. Armstrong¹, L. Means¹, E. Petersen¹, K. E. Resnick¹ and R. DeBernardo²
¹University Hospitals Case Medical Center, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH

4:05 PM

231 - Poster Session A

Correlation of positron emission tomography (PET) with CA-125 levels in predicting recurrence in ovarian cancer

J. M. Scalici¹, B. Henderson², B. Wang¹, M. A. Finan¹ and R. P. Rocconi¹
¹University of South Alabama, Mobile, AL, ²University of South Alabama Mitchell Cancer Institute, Mobile, AL

4:25 PM

232 - Poster Session A

Identification of differentially expressed miRNAs in ovarian cancer from endometriosis in the same patient

R. Wu¹, Q. F. Ahmed¹, S. Ali², B. Alosh¹, Z. Al-Wahab¹, I. Winer¹, S. Bandyopadhyay¹, F. Sarkar², R. T. Morris¹ and R. Ali-Fehmi¹
¹Wayne State University, Detroit, MI, ²Karmanos Cancer Institute, Detroit, MI

4:45 PM

233 - Poster Session A

Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors

A. E. Garcia-Soto¹, J. A. Lucci III², E. Podack², T. Schreiber³ and E. D. Schroeder⁴
¹University of Miami Jackson Memorial Hospital, Miami, FL, ²University of Miami Miller School of Medicine, Miami, FL, ³University of Miami Miller School of Medicine, miami, FL, ⁴University of Miami-Jackson Memorial Hospital, Miami, FL

5:05 PM

234 - Poster Session A

Reliability and reproducibility of ^99mTc-etarfolatide for identification of patient folate receptor status

P. Kuo¹, R. Van Heertum², B. Nguyen³, J. Symanowski⁴ and R. W. Naumann⁴
¹University of Arizona, Tucson, AZ, ²Bioclinica, Inc, Princeton, NJ, ³Endocyte, Inc, West Lafayette, IN, ⁴Levine Cancer Institute, Charlotte, NC

5:25 PM

235 - Poster Session A

HGF/c-Met axis drives cancer aggressiveness in the neoadjuvant setting of ovarian cancer

S. Shahabi¹, M. Mariani², M. McHugh³, S. Sieber³, P. Fiedler³ and C. Ferlini¹
¹Western Connecticut Health Network/Danbury Hospital, Danbury, CT, ²Western Connecticut Health Network/Danbury Hospital, Danbury, CT, ³Western CT Health Network/Danbury Hospital, Danbury, CT

5:45 PM

236 - Poster Session A

Hitting the right mark: nonoverlapping Notch and PI3K alterations in ovarian cancer

A. N. Davis, C. Ivan, R. A. Previs, H. J. Dalton, J. N. Bottsford-Miller, B. Zand, R. L. Coleman, K. A. Baggerly and A. K. Sood
The University of Texas MD Anderson Cancer Center, Houston, TX

6:05 PM

237 - Poster Session A

Clinicopathologic benchmark for prognostic modeling of advanced epithelial ovarian cancer long-term survival: a Gynecologic Oncology Group (GOG) analysis

Y. Casablanca¹, A. Miller², N. S. Horowitz³, B. J. Rungruang⁴, T. C. Krivak⁵, S. D. Richard⁶, N. Rodriguez⁷, M. A. Bookman⁸, G. L. Maxwell⁹ and C. A. Hamilton¹
¹Walter Reed National Military Medical Center, Bethesda, MD, ²Gynecologic Oncology Group, Buffalo, NY, ³Harvard University, Boston, MA, ⁴Georgia Reagents University, Evans, GA, ⁵Western Pennsylvania Hospital, Pittsburgh, PA, ⁶Hahnemann University Hospital/Drexel University College of Medicine, Philadelphia, PA, ⁷Loma Linda University Medical Center, Loma Linda, CA, ⁸University of Arizona Cancer Center, Tucson, AZ, ⁹Inova Fairfax Hospital, Falls Church, VA

6:25 PM

238 - Poster Session A

Serum antibodies recognizing BRCA1 at time of diagnosis and primary platinum resistance in ovarian cancer

J. B. Liao¹, K. J. Ovenell¹, M. Wu¹, K. J. Agnew², M. I. Harrell¹, E. M. Swisher², B. A. Goff² and M. L. Disis¹
¹University of Washington, Seattle, WA, ²University of Washington Medical Center, Seattle, WA

6:45 PM

239 - Poster Session A

Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer

R. S. Suidan¹, Q. Zhou¹, A. Iasonos², R. O'Cearbhaill², D. S. Chi², K. C. Long², E. J. Tanner III², J. Denesopolis¹, R. R. Barakat² and O. Zivanovic¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Memorial Sloan-Kettering Cancer Center, New York, NY

7:05 PM

240 - Poster Session A

Venous thromboembolism carries a particularly grave prognosis with epithelial ovarian cancer

C. C. Gunderson¹, E. D. Thomas², K. N. Slaughter¹, R. Farrell¹, K. Ding¹, J. K. Lauer¹, L. Perry¹, D. S. McMeekin¹ and K. N. Moore¹
¹The University of Oklahoma, Oklahoma City, OK, ²Stephenson Cancer Center, The University of Oklahoma, Oklahoma City, OK

7:25 PM

241 - Poster Session A

Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

D. P. English, C. L. Schwab, D. M. Roque, S. Bellone, E. S. Ratner, D. A. Silasi, M. Azodi, P. E. Schwartz, T. J. Rutherford and A. Santin
Yale University School of Medicine, New Haven, CT

7:45 PM

242 - Poster Session A

Inhibition of HIF1a promotes paclitaxel efficacy in CD133+ ovarian carcinoma cells

T. Okamoto¹, Z. Huang¹, R. Whitaker¹, I. Konishi², A. Berchuck¹ and S. K. Murphy¹
¹Duke University, Durham, NC, ²Kyoto University, Kyoto, Japan

8:05 PM

243 - Poster Session A

The utilization of positron emission tomography (PET) scans in ovarian, fallopian tube, and primary peritoneal carcinoma patients may be associated with improved overall survival

N. Rasool, Y. Wang, R. K. Hanna, T. E. Buekers, A. R. Munkarah and S. Hensley Alford
Henry Ford Health System, Detroit, MI

8:25 PM

244 - Poster Session A

Prognostic factors for overall survival in recurrent ovarian, Fallopian tube, and peritoneal cancer patients treated with bevacizumab: a multisite study

M. D. Dao¹, E. Zsiros², R. R. Urban¹, H. J. Gray¹, H. K. Tamimi¹, B. A. Goff¹, J. L. Tanyi² and J. B. Liao³
¹University of Washington Medical Center, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³University of Washington, Seattle, WA

8:45 PM

245 - Poster Session A

Prognostic factors in malignant ovarian germ cell tumors

G. Baiocchi¹, G. Ritt², H. Mantoan¹, M. Macedo², L. De Brot¹, C. Faloppa¹ and E. Fukazawa¹
¹A.C. Camargo Cancer Center, Săo Paulo, Brazil, ²A.C. Camargo Cancer Center, Sao Paulo, Brazil

9:05 PM

246 - Poster Session A

A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer

R. S. Suidan¹, C. St. Clair², S. J. Lee¹, J. N. Barlin², K. C. Long², E. J. Tanner III², Y. Sonoda², R. R. Barakat², O. Zivanovic¹ and D. S. Chi²
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Memorial Sloan-Kettering Cancer Center, New York, NY

9:25 PM

247 - Poster Session A

Nomogram predicting 5-year progression-free survival after secondary surgical cytoreduction for platinum-sensitive recurrent ovarian cancer

C. H. Kim¹, L. Kou², C. Yu², J. S. Taylor³, O. Zivanovic⁴, R. R. Barakat⁵, V. Makker⁵, M. W. Kattan² and D. S. Chi⁵
¹Thomas Jefferson University Hospital, Philadelphia, PA, ²The Cleveland Clinic, Cleveland, OH, ³New York-Presbyterian Hospital - Weill Cornell Medical College, New York, NY, ⁴Memorial Sloan Kettering Cancer Center, New York, NY, ⁵Memorial Sloan-Kettering Cancer Center, New York, NY

9:45 PM

248 - Poster Session A

Lymphadenectomy in stage I ovarian granulosa cell tumors improves overall survival

S. E. Taylor¹, M. Courtney-Brooks², M. Quimper¹, J. T. Comerci¹, A. B. Olawaiye¹, J. L. Kelley III², M. Huang¹ and P. Sukumvanich¹
¹Magee-Womens Hospital of UPMC, Pittsburgh, PA, ²University of Pittsburgh Medical Center, Pittsburgh, PA

10:05 PM

249 - Poster Session A

Risk of second primary breast cancer among women with epithelial ovarian cancer compared to fallopian tube cancer

J. A. Rauh-Hain¹, J. T. Clemmer¹, R. M. Clark¹, T. R. Hall², W. B. Growdon², D. M. Boruta II¹, A. Goodman¹, J. O. Schorge¹ and M. G. Del Carmen¹
¹Massachusetts General Hospital/Harvard University, Boston, MA, ²Massachusetts General Hospital, Boston, MA

10:25 PM

250 - Poster Session A

Predicting overall survival after secondary surgical cytoreduction for platinum-sensitive recurrent ovarian cancer: a prognostic nomogram

C. H. Kim¹, L. Kou², C. Yu², E. Conroy³, C. L. Brown⁴, N. R. Abu-Rustum⁴, G. J. Gardner⁴, V. Makker⁵, M. W. Kattan² and D. S. Chi⁵
¹Thomas Jefferson University Hospital, Philadelphia, PA, ²The Cleveland Clinic, Cleveland, OH, ³Albert Einstein Montefiore Medical Center, New York, NY, ⁴Memorial Sloan Kettering Cancer Center, New York, NY, ⁵Memorial Sloan-Kettering Cancer Center, New York, NY

10:45 PM

251 - Poster Session A

Acquired platinum resistance among women with high-grade serous epithelial ovarian cancer

K. N. Slaughter¹, C. C. Gunderson¹, L. Perry¹, E. D. Thomas², R. Farrell¹, J. K. Lauer¹, K. Ding¹, D. S. McMeekin¹ and K. N. Moore¹
¹The University of Oklahoma, Oklahoma City, OK, ²Stephenson Cancer Center, The University of Oklahoma, Oklahoma City, OK

11:05 PM

252 - Poster Session A

Differential expression of Rad51 and NAC1 proteins in primary, metastatic, and recurrent high-grade serous ovarian cancer

H. Mahdi¹, P. G. Rose¹ and B. Yang²
¹Cleveland Clinic, Cleveland, OH, ²The Cleveland Clinic, Cleveland, OH

11:25 PM

253 - Poster Session A

Radiation therapy for recurrent clear cell ovarian carcinoma

G. Westhoff¹, K. C. Fuh², T. A. Longacre², L. McNally², I. C. Hsu¹, D. S. Kapp², N. N. H. Teng³ and L. M. Chen¹
¹UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, ²Stanford University, Stanford, CA, ³Stanford University Medical Center, Stanford, CA

11:45 PM

254 - Poster Session A

An analysis of the survival outcomes of video-assisted thoracic surgery in the primary management of patients with advanced ovarian, tubal, and peritoneal cancer

J. A. Ducie¹, J. Lee², O. Zivanovic¹, G. J. Gardner¹, M. M. Leitao¹, D. A. Levine¹, Y. Sonoda³, N. R. Abu-Rustum¹, R. Downey³ and D. S. Chi³
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Hofstra - North Shore Long Island Jewish School of Medicine, Manhasset, NY, ³Memorial Sloan-Kettering Cancer Center, New York, NY

12:05 AM

255 - Poster Session A

Canine scent-specific detection of serous ovarian cancer

A. F. Burnett¹, R. L. Stone¹ and D. Waugh²
¹University of Arkansas for Medical Sciences, Little Rock, AR, ²American Scent Dog Association, Little Rock, AR

12:25 AM

256 - Poster Session A

Robotic and open cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of recurrent ovarian carcinoma

J. P. Diaz¹, J. Kreafle², K. Angel¹, R. A. Estape¹, E. D. Schroeder³ and R. E. Estape⁴
¹South Miami Gynecologic Oncology Group, Miami, FL, ²University of Miami School of Medicine, Miami, FL, ³University of Miami-Jackson Memorial Hospital, Miami, FL, ⁴South Miami Hospital, Miami, FL

12:45 AM

Translational Research/Basic Science

1:05 AM

257 - Poster Session A

Development of flow cytometric predictive biomarker assay for response to PARP inhibitor (PARPi) therapy in high-grade serous ovarian cancer (HGSOC)

J. M. Lee, N. Gordon, M. J. Lee, J. Trepel, M. Yu and E. C. Kohn
National Cancer Institute, Bethesda, MD

1:25 AM

258 - Poster Session A

Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy

I. Wilkinson-Ryan¹, J. Kim², S. Kim¹, M. A. Powell¹, D. G. Mutch¹, D. Spitzer¹, T. Hansen¹, S. P. Goedebeuure¹, D. T. Curiel¹ and W. Hawkins¹
¹Washington University School of Medicine, St. Louis, MO, ²University of Chicago, Chicago, IL

1:45 AM

259 - Poster Session A

Magneto-electric nanoparticles as field-controlled nano-electroporation sites for high specificity

S. Khizroev
Florida International University, Miami, FL

2:05 AM

260 - Poster Session A

Treatment of epithelial ovarian cancer with HE4-targeted antisense phosphorothioligos (PTOs)

E. Lokich¹, E. K. Hill¹, A. Han², N. Romano¹, T. Horan¹, N. Yano², K. Kim², R. Singh² and R. G. Moore¹
¹Women & Infants' Hospital, Brown University, Providence, RI, ²Women and Infants Hospital, Brown University, Providence, RI

2:25 AM

261 - Poster Session A

Intraperitoneal administration of alpha-emitting isotopes

J. Rotmensch and S. B. Dewdney
Rush University Medical Center, Chicago, IL

2:45 AM

262 - Poster Session A

Impact of new oncolytic herpes simplex virus for cervical cancer therapy

M. Kagabu, Y. Miura, R. Takeshita, N. Yoshino and T. Sugiyama
Iwate Medical University, Morioka, Japan

3:05 AM

263 - Poster Session A

BRCA1 mutation determines the impact of profilin1 in ovarian cancer cell motility

J. L. Lesnock^1,2, D. Gau², T. C. Krivak³, J. L. Kelley III⁴, R. P. Edwards⁴ and P. Roy²
¹Mid Atlantic Gynecologic Oncology of Mon General Hospital, Morgantown, WV, ²University of Pittsburgh, Pittsburgh, PA, ³Western Pennsylvania Hospital, Pittsburgh, PA, ⁴Magee-Womens Hospital of UPMC, Pittsburgh, PA

3:25 AM

264 - Poster Session A

Yes-associated protein (YAP) functions as a proto-oncogene and promotes radiation resistance in endometrial cancer

M. Tsujiura¹, V. Mazack¹, M. Sudol¹, D. J. Carey¹, J. D. Nash², H. G. Kaspar² and R. Gogoi²
¹Weis Center for Research, Geisinger Clinic, Danville, PA, ²Geisinger Clinic, Danville, PA

3:45 AM

265 - Poster Session A

Somatic mutations in small cell carcinoma of the ovary

J. J. Mueller¹, P. Jelinic¹, N. Olvera², F. Dao¹, R. A. Soslow¹, M. F. Berger² and D. A. Levine¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Memorial Sloan-Kettering Cancer Center, New York, NY

4:05 AM

266 - Poster Session A

Detection of ovarian cancer biomarkers in routine Pap tests by mass spectrometry-based proteomic techniques

A. P. N. Skubitz, K. L. M. Boylan, S. Afiuni, T. J. Griffin and M. A. Geller
University of Minnesota, Minneapolis, MN

4:25 AM

267 - Poster Session A

Inhibition of autophagy by vaginal fluid from women with malignant adnexal masses

T. Orfanelli, G. Doulaveris, J. M. Jeong, K. M. Holcomb, T. A. Caputo, D. Gupta and S. S. Witkin
Weill Cornell Medical College, New York, NY

4:45 AM

268 - Poster Session A

Frequent inactivation of the XAF1 tumor suppressor gene in human ovarian cancer by aberrant promoter CpG sites hypermethylation

K. D. Ki¹ and J. M. Lee²
¹Kyung Hee University Hospital at Gangdong, Seoul, South Korea, ²Kyung Hee University, Seoul, South Korea

5:05 AM

269 - Poster Session A

Enhanced gynecologic cancer cell killing through pharmacologic inhibition of the ataxia telangiectasia and Rad3-related kinase

P. N. Teng¹, N. W. Bateman¹, K. A. Conrads¹, K. E. Oliver², C. A. Hamilton², G. L. Maxwell³, C. J. Bakkenist⁴ and T. P. Conrads¹
¹Gynecologic Cancer Center of Excellence, Annandale, VA, ²Walter Reed National Military Medical Center, Bethesda, MD, ³Inova Fairfax Hospital, Falls Church, VA, ⁴University of Pittsburgh, Pittsburgh, PA

5:25 AM

270 - Poster Session A

HE4 interacts with sex hormones in epithelial ovarian cancer

E. Lokich¹, A. Han², N. Romano¹, N. Yano², K. Kim², R. Singh² and R. G. Moore¹
¹Women & Infants' Hospital, Brown University, Providence, RI, ²Women and Infants Hospital, Brown University, Providence, RI

5:45 AM

271 - Poster Session A

Novel mechanisms of chemoresistance in ovarian cancer: the role of tunneling nanotubes

E. L. Dickson, V. Thayanithy, P. Wong, D. G. K. Teoh, P. A. Argenta, R. Isaksson Vogel, C. Steer, M. A. Geller, S. Subramanian and E. Lou
University of Minnesota, Minneapolis, MN

6:05 AM

272 - Poster Session A

FBxW7 duality in ovarian cancer: novel insight into ovarian cancer pathogenesis

E. L. Dickson¹, L. Li¹, S. Leung², C. Chow², R. Isaksson Vogel¹, D. Huntsman³, B. Gilks³ and S. Subramanian¹
¹University of Minnesota, Minneapolis, MN, ²The University of British Columbia, Vancouver, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada

6:25 AM

273 - Poster Session A

Progestin and vitamin D suppress growth of ovarian cancer in vitro and in vivo

J. Hunn^1,2, J. Turbov², R. Rosales², V. Syed³, C. A. Hamilton⁴, G. L. Maxwell⁵, L. G. Thaete^1,2 and G. C. Rodriguez^1,2
¹University of Chicago, Chicago, IL, ²Northshore University Health System, Evanston, IL, ³Uniformed Services University of the Health Sciences, Bethesda, MD, ⁴Walter Reed National Military Medical Center, Bethesda, MD, ⁵Inova Fairfax Hospital, Falls Church, VA

6:45 AM

274 - Poster Session A

The PI3K inhibitor GDC-0941 is synergistic with lapatinib and mediates endocrine sensitivity in uterine papillary serous carcinoma via AKT

K. Levano¹, A. G. Rodriguez-Gabin², Y. Wang³, M. H. Einstein³, G. L. Goldberg³, S. B. Horwitz² and J. Y. Hou³
¹Peruvian National Institute of Health, Lima 9, Peru, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

7:05 AM

275 - Poster Session A

Subcellular localization and function of insulin-like growth factor 2 (IGF2) in uterine carcinosarcoma

J. A. Heim¹, S. Mi¹, M. Cossio-Poblete¹, J. Brouwer-Visser¹, Y. Wang¹, M. J. Gunter² and G. S. Huang^1,3
¹Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²Imperial College London, London, United Kingdom, ³Albert Einstein Cancer Center, Bronx, NY

7:25 AM

276 - Poster Session A

The HMG-CoA reductase inhibitor simvastatin exhibits antitumorigenic and antimetastatic effects in ovarian cancer

J. E. Stine, X. Han, M. Schointuch, C. Zhou, T. Gilliam, P. A. Gehrig and V. L. Bae-Jump
University of North Carolina at Chapel Hill, Chapel Hill, NC

7:45 AM

277 - Poster Session A

Simvastatin, an HMG-CoA reductase inhibitor, exhibits antimetastatic and antitumorigenic effects in endometrial cancer

J. E. Stine, M. Schointuch, C. Zhou, T. Gilliam, X. Han, P. A. Gehrig and V. L. Bae-Jump
University of North Carolina at Chapel Hill, Chapel Hill, NC

8:05 AM

278 - Poster Session A

Binary methylation of human papillomavirus (HPV) L1 and death-associated protein kinase (DAPK) as biomarkers of progression in cervical carcinogenesis

S. M. Jordan¹, M. Kalantari², H. U. Bernard², I. Calleja-Macias², S. Kim², D. Chase³ and K. S. Tewari⁴
¹University of California at Irvine Medical Center, Orange, CA, ²University of California, Irvine, Irvine, CA, ³St. Joseph Hospital and Medical Center, Phoenix, AZ, ⁴University of California at Irvine, Irvine, CA

8:25 AM

279 - Poster Session A

Targeting myeloid cells in the tumor microenvironment as a strategy to enhance vaccine efficacy in epithelial ovarian cancer

N. V. Kolomeyevskaya, N. Khan, M. Grimm, K. Singel, K. S. Grzankowski, S. Abrams, K. O. Odunsi and B. H. Segal
Roswell Park Cancer Institute, Buffalo, NY

8:45 AM

280 - Poster Session A

Cytokine profiling of ascites identifies macrophage inflammatory protein-beta and tumor necrosis factor–alpha as predictors of progression-free survival in patients with epithelial ovarian cancer

N. V. Kolomeyevskaya, N. Khan, R. Dolnick, S. Abrams, K. O. Odunsi, S. B. Lele and B. H. Segal
Roswell Park Cancer Institute, Buffalo, NY

9:05 AM

281 - Poster Session A

Expression of GPER, ERβ, ERα, and PR in gynecologic sarcomas

M. Klobocista¹, R. Phaeton¹, E. R. Burton², A. R. Van Arsdale¹, T. Hebert¹, H. O. Smith¹, H. Arias-Pulido³, E. Prossnitz⁴, G. L. Goldberg¹ and G. S. Huang¹
¹Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²Abington Memorial Hospital, Hanjani Institute for Gynecologic Oncology, Abington, PA, ³Complex Biological Systems Alliance, North Andover, MA, ⁴University of New Mexico Health Sciences Center, Albuquerque, NM

9:25 AM

282 - Poster Session A

Ovarian cancers with nuclear special AT-rich sequence-binding protein 1 and cytoplasmic AT-rich interactive domain-containing protein 1A are rare, drug-resistant, and deadly

E. A. Dubil¹, W. Bshara², K. O. Odunsi², C. Morrison², C. Tian^3,4, J. I. Risinger⁵, G. L. Maxwell⁶, C. A. Hamilton¹, K. M. Darcy⁷ and W. Consortium³
¹Walter Reed National Military Medical Center, Bethesda, MD, ²Roswell Park Cancer Institute, Buffalo, NY, ³Women's Health Integrated Research Center, Annandale, VA, ⁴Precision Therapeutics, Inc., Pittsburgh, PA, ⁵Michigan State University, Grand Rapids, MI, ⁶Inova Fairfax Hospital, Falls Church, VA, ⁷Gynecologic Cancer Center of Excellence, Annandale, VA

9:45 AM

283 - Poster Session A

Putative events in the development of clear cell ovarian carcinoma from endometriosis: an evaluation using immunohistochemistry and gene expression profiling

M. J. Worley Jr.¹, S. Liu², Y. Hua², A. Samuel², C. E. Parra-Herran¹, W. R. Welch¹, C. P. Crum¹, R. S. Berkowitz¹ and S. W. Ng²
¹Brigham and Women's Hospital/Harvard University, Boston, MA, ²Brigham & Women's Hospital, Boston, MA

10:05 AM

284 - Poster Session A

Selective activation of Notch3 in high-grade serous ovarian cancer

W. Hu, T. Liu, C. Ivan, J. Huang, H. J. Dalton, R. A. Previs, A. M. Nick, G. Lopez-Berestein, R. L. Coleman and A. K. Sood
The University of Texas MD Anderson Cancer Center, Houston, TX

10:25 AM

285 - Poster Session A

PARP inhibition synergizes with anti-CTLA-4 immune therapy to promote rejection of peritoneal tumors in mouse models of ovarian cancer

T. Higuchi¹, D. Flies¹, G. M. Mantia-Smaldone², P. L. Ronner³, J. Alldredge¹, S. Orsulic⁴ and S. F. Adams¹
¹University of New Mexico, Albuquerque, NM, ²Fox Chase Cancer Center, Philadelphia, PA, ³Carnegie Mellon University, Pittsburgh, PA, ⁴Cedars-Sinai Medical Center, Los Angeles, CA

10:45 AM

286 - Poster Session A

Tumor cells surviving the cytotoxic effect of paclitaxel are sensitized to anti-cancer peptide PNC-27

I. Alagkiozidis¹, E. Sarafraz-Yazdi², M. Lozano², Y. C. Lee¹, O. Abulafia¹ and J. Michl²
¹SUNY Downstate, Brooklyn, NY, ²SUNY-Downstate, Brooklyn, NY

11:05 AM

287 - Poster Session A

Testing the accuracy of mutation detection for the prevention of ovarian neoplasia: the TAMPON study

B. K. Erickson¹, Z. C. Dobbin¹, I. Kinde², J. Y. Martin¹, Y. Wang², R. Roden², W. K. Huh¹, B. Vogelstein², L. A. Diaz² and C. N. Landen Jr.¹
¹University of Alabama at Birmingham, Birmingham, AL, ²Johns Hopkins University, Baltimore, MD

11:25 AM

288 - Poster Session A

Dual HER2 targeting impedes growth of HER2 gene-amplified uterine papillary serous carcinoma xenografts

W. B. Growdon¹, J. W. Groeneweg¹, V. F. Byron¹, S. F. Hernandez¹, D. R. Borger¹, R. Tambouret¹, J. O. Schorge², M. G. Del Carmen², R. Foster¹ and B. R. Rueda¹
¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital/Harvard University, Boston, MA

11:45 AM

289 - Poster Session A

Use of SRC pathway activation in predicting dasatinib activity in ovarian cancer

A. Wallace¹, D. Corcoran², M. Lopez¹, D. G. K. Teoh³, D. Adams¹, L. Grace¹ and A. A. Secord¹
¹Duke University Medical Center, Durham, NC, ²Duke Institute for Genome Sciences and Policy, Durham, NC, ³University of Minnesota, Minneapolis, MN

12:05 PM

290 - Poster Session A

Analysis of the immune cell composition in serous ovarian cancer

C. J. Stashwick, A. F. Haggerty, G. Kari, T. Garrabrant, A. Best, K. S. Tan, W. T. Hwang, G. Coukos and D. J. Powell Jr.
University of Pennsylvania, Philadelphia, PA

12:25 PM

291 - Poster Session A

Patient-derived tumor xenograft model (“avatar mice”) for gynecologic cancer

J. W. Lee¹, Y. J. Cho², S. Y. Song¹, B. G. Kim³ and D. S. Bae¹
¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Samsung Medical Center, Seoul, South Korea, ³Sungkyunkway University School of Medicine, Seoul, South Korea

12:45 PM

292 - Poster Session A

The microenvironmental effects of endometriosis on VCAM1 and IL-10 expression in early stage epithelial ovarian cancer

J. Nakayama¹, L. Duska¹, K. A. Atkins², J. M. Scalici³, M. Smolkin⁴, M. Conaway⁵ and J. K. Slack-Davis⁵
¹University of Virginia Health System, Charlottesville, VA, ²University of Virginia Medical Center, Charlottesville, VA, ³University of South Alabama, Mobile, AL, ⁴University of Virginia School of Medicine, Charlottesville, VA, ⁵University of Virginia, Charlottesville, VA

1:05 PM

293 - Poster Session A

Serum omentin concentration is a potential biomarker for complex atypical hyperplasia and endometrioid endometrial cancer

L. L. Holman, M. Onstad, Q. Zhang, R. E. Schmandt, S. Neal, M. F. Munsell, D. Urbauer, S. Mok and K. H. Lu
The University of Texas MD Anderson Cancer Center, Houston, TX

1:25 PM

294 - Poster Session A

mTOR complex inhibition as a novel therapeutic strategy in high-grade papillary serous ovarian cancer

F. Musa¹, A. Alard², S. V. Blank¹, B. Pothuri¹, J. P. Curtin¹ and R. Schneider¹
¹New York University School of Medicine, New York, NY, ²New York University Sackler Institute of Biomedical Sciences, New York, NY

1:45 PM

295 - Poster Session A

Curated Ovarian Database-derived identification of genes predicting survival in primary serous epithelial ovarian cancer

N. T. Phippen¹, G. Wang², N. W. Bateman², T. Litzi², W. J. Lowery¹, A. Berchuck³, G. L. Maxwell⁴, C. A. Hamilton¹, T. P. Conrads² and K. M. Darcy²
¹Walter Reed National Military Medical Center, Bethesda, MD, ²Gynecologic Cancer Center of Excellence, Annandale, VA, ³Duke University, Durham, NC, ⁴Inova Fairfax Hospital, Falls Church, VA

2:05 PM

296 - Poster Session A

Cytokine-induced killer cells from ovarian cancer patients expanded ex vivo in the presence of IL-7 improve survival in a xenograft mouse model of ovarian cancer

S. B. Ingersoll¹, M. Srivastava¹, G. Ali¹, Z. Mohiuddin¹, E. R. Boone¹, S. Ahmad¹, R. K. Banks², N. J. Finkler¹, J. R. Edwards³ and R. W. Holloway¹
¹Florida Hospital Cancer Institute, Orlando, FL, ²University of Central Florida, Orlando, FL, ³Indiana Blood and Marrow Transplantation, Indianapolis, IN

2:25 PM

297 - Poster Session A

Wnt pathway inhibition by niclosamide: a therapeutic target for ovarian cancer

R. C. Arend¹, C. L. Walters Haygood¹, Y. Li², C. Kurpad¹, A. Gangrade¹, M. Straughn¹ and D. J. Buchsbaum¹
¹University of Alabama at Birmingham, Birmingham, AL, ²Southern Research Institute, Birmingham, AL

2:45 PM

298 - Poster Session A

PARP therapy for the genetically unstable: a preclinical evaluation of PARP inhibitors in the treatment of MSI-H endometrial tumors

K. L. Ring, A. E. Guzman, R. E. Schmandt and K. H. Lu
The University of Texas MD Anderson Cancer Center, Houston, TX

3:05 PM

299 - Poster Session A

Copy number variation and mutations associated with ovarian cancer chemoresponse

N. Bou Zgheib¹, D. Marchion², P. L. Judson Lancaster², R. M. Wenham², S. M. Apte², J. M. Lancaster² and J. G. Bosquet³
¹University of South Florida College of Medicine, Tampa, FL, ²H. Lee Moffitt Cancer Center, Tampa, FL, ³Mayo Graduate School of Medicine, Jacksonville, FL

3:25 PM

300 - Poster Session A

Ovarian cancer ascites stem cell population compared to primary tumor

C. L. Walters Haygood, R. C. Arend, A. Londono-Joshi, C. Kurpad, A. A. Katre, M. G. Conner, C. N. Landen Jr., J. M. Straughn Jr. and D. J. Buchsbaum
University of Alabama at Birmingham, Birmingham, AL

3:45 PM

301 - Poster Session A

HSP90 inhibition decreases ovarian cancer cell proliferation and potentiates platinum sensitivity

F. Abbasi¹, D. Marchion¹, Y. Xiong¹, S. H. Bush², E. Al Sawah², S. S. Al Rubaish¹, I. Ramirez², N. Bou Zgheib², R. M. Wenham¹ and J. M. Lancaster¹
¹H. Lee Moffitt Cancer Center, Tampa, FL, ²University of South Florida College of Medicine, Tampa, FL

4:05 PM

302 - Poster Session A

Expression profiles of LKB1/AMPK in endometrial cancer specimens as a potential biomarker for targeted metabolic drug therapy

I. S. Okon¹, K. N. Slaughter², B. Scott², D. S. McMeekin² and D. M. Benbrook¹
¹The University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²The University of Oklahoma, Oklahoma City, OK

4:25 PM

303 - Poster Session A

Radioimmunotherapy targeting human papillomavirus E7 oncoprotein demonstrates therapeutic potential and limited toxicity

J. F. Gutierrez¹, R. Phaeton², Z. Jiang¹, G. L. Goldberg² and E. Dadachova¹
¹Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

4:45 PM

304 - Poster Session A

ALDH1A1 maintains ovarian cancer stem-like cells' properties by regulating KLF4/p21-mediated signaling cascade

E. Meng¹, A. Mitra¹, S. McClellan¹, J. M. Scalici², K. Palle¹, L. Shevde³ and R. P. Rocconi²
¹University of South Alabama Mitchell Cancer Institute, Mobile, AL, ²University of South Alabama, Mobile, AL, ³University of Alabama at Birmingham, Birmingham, AL

5:05 PM

305 - Poster Session A

A Hedgehog pathway smoothened inhibitor demonstrates synergy with carboplatin in ovarian cancer via a dual process of receptor enrichment plus regulation of DNA damage processing

E. Meng¹, A. Mitra¹, J. M. Scalici², K. Palle¹, L. Shevde³ and R. P. Rocconi²
¹University of South Alabama Mitchell Cancer Institute, Mobile, AL, ²University of South Alabama, Mobile, AL, ³University of Alabama at Birmingham, Birmingham, AL

5:25 PM

306 - Poster Session A

Pharmacologic inhibition of polo-like kinase 1 enhances paclitaxel-based cell killing in taxol-resistant ovarian cancer cells

C. S. Marcus¹, B. L. Hood², G. Wang², N. W. Bateman², K. A. Conrads², E. A. Dubil¹, K. M. Darcy², G. L. Maxwell³, C. A. Hamilton¹ and T. P. Conrads²
¹Walter Reed National Military Medical Center, Bethesda, MD, ²Gynecologic Cancer Center of Excellence, Annandale, VA, ³Inova Fairfax Hospital, Falls Church, VA

5:45 PM

307 - Poster Session A

Establishment and combined genomic and proteomic characterization of patient-derived ovarian cancer cell lines

E. B. Pereira, B. Evans, O. C. Vanegas, P. Dottino and J. Martignetti
Icahn School of Medicine at Mount Sinai, New York, NY

6:05 PM

308 - Poster Session A

Initial investigation of combined single-photon emission computed tomography (SPECT) and magnetic resonance (MR) imaging of a human ovarian tumor xenograft using ¹²³I-bevacizumab

L. M. Randall¹, M. J. Hamamura², D. H. Harris³, S. Ha⁴, W. Roeck⁴ and O. Nalcioglu⁴
¹University of California at Irvine Medical Center, Orange, CA, ²University of California Irvine, Irvine, CA, ³Sandoz Biopharmaceuticals, Unterach, Austria, ⁴Tu & Yuen Center for Functional Onco-Imaging, Irvine, CA

6:25 PM

309 - Poster Session A

Identification of microscopic ovarian tumor foci utilizing a novel imaging device in a murine ovarian cancer model: an opportunity to improve optimal cytoreduction

C. S. Awtrey¹, Y. J. Na², J. Ferrer³, D. Strasfeld³ and M. J. Birrer⁴
¹Beth Israel Deaconess Medical Center, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Lumicell Diagnostics, Inc, Wellesley, MA, ⁴Massachusetts General Hospital Cancer Center/Harvard University, Boston, MA

6:45 PM

Uterine/Endometrial Cancer

7:05 PM

310 - Poster Session A

An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high-volume cancer centers

T. J. Vogel^1,2, A. Knickerbocker¹, C. A. Shah³, M. A. Schiff¹, C. Isacson⁴, R. L. Garcia¹ and B. A. Goff¹
¹University of Washington Medical Center, Seattle, WA, ²Women’s Cancer Program/ Cedars-Sinai Medical Center, Los Angeles, CA, ³Pacific Gynecology Specialists, Seattle, WA, ⁴CellNetix Pathology and Laboratories, Seattle, WA

7:25 PM

311 - Poster Session A

Incidence of ovarian metastases in uterine leiomyosarcoma and optimal surgery

I. R. Gagua
National Cancer Center of Georgia, Tbilisi, Georgia

7:45 PM

312 - Poster Session A

Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases

A. Yoon¹, D. S. Bae², B. G. Kim², J. W. Lee², Y. Y. Lee¹ and C. H. Choi¹
¹Samsung Medical Center, Seoul, South Korea, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

8:05 PM

313 - Poster Session A

Is rad/let/met more than just a catchy name? A preclinical evaluation of everolimus, letrozole, and metformin in recurrent endometrial cancer

K. L. Ring, J. Celestino, M. Yates, Q. Zhang, R. E. Schmandt and K. H. Lu
The University of Texas MD Anderson Cancer Center, Houston, TX

8:25 PM

314 - Poster Session A

Defining optimal combinations of PI3K/Akt/mTOR and Ras/Raf/MAPK pathway inhibitors for use in endometrial cancer

S. S. Isani¹, A. G. Rodriguez-Gabin², G. L. Goldberg³, S. B. Horwitz² and H. M. McDaid²
¹Rutgers Cancer Institute of New Jersey/ Robert Wood Johnson Medical School, New Brunswick, NJ, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

8:45 PM

315 - Poster Session A

Effective endometrial cancer screening method using liquid-based cytology

T. Kurokawa, A. Sinagawa and Y. Yoshida
University of Fukui, Fukui, Japan

9:05 PM

316 - Poster Session A

A comparison of colorimetric versus fluorometric sentinel lymph node mapping during robotic surgery for endometrial cancer

A. K. Sinno, K. C. Long, A. Nickles Fader, R. L. Giuntoli II and E. J. Tanner III
Johns Hopkins Medical Institutions, Baltimore, MD

9:25 PM

317 - Poster Session A

Survival impact of cytoreduction to microscopic disease for advanced-stage cancer of the uterine corpus

I. Alagkiozidis¹, N. Zhining², M. Lozano², B. B. Mize¹, K. Economos³, G. M. Salame¹, Y. C. Lee¹ and O. Abulafia¹
¹SUNY Downstate, Brooklyn, NY, ²SUNY-Downstate, Brooklyn, NY, ³New York Methodist Hospital, Brooklyn, NY

9:45 PM

318 - Poster Session A

Successful identification of high-risk grade 1 endometrial cancer utilizing MRI, CA-125 and BMI before surgery: a prospective quality improvement initiative

A. N. Al-Niaimi¹, N. A. Onujiogu¹, E. Sadowski², K. Guite², K. Patel-Lippmann², E. M. Hartenbach¹, L. M. Barroilhet¹, S. L. Rose¹, L. W. Rice¹ and D. M. Kushner¹
¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, Madison, WI

10:05 PM

319 - Poster Session A

Extent of lymph node dissection and overall survival in patients with uterine carcinosarcoma, papillary serous, and endometrioid adenocarcinoma

I. Alagkiozidis¹, J. Jaffe², M. Lozano², B. B. Mize¹, C. Gorelick³, G. M. Salame¹, O. Abulafia¹ and Y. C. Lee¹
¹SUNY Downstate, Brooklyn, NY, ²SUNY-Downstate, Brooklyn, NY, ³NY Methodist Hospital - Affiliate of Cornell Medical College, Brooklyn, NY

10:25 PM

320 - Poster Session A

Analyzing the learning curve of robotic-assisted sentinel lymph node dissection for endometrial cancer

P. H. Desai, P. Hughes, K. Graebe, N. Tchabo, D. H. Tobias, P. B. Heller and B. M. Slomovitz
Women's Cancer Center, Carol G Simon Cancer Center, Morristown, NJ

10:45 PM

321 - Poster Session A

Does ultrastaging improve detection of micrometastasis for early-stage endometrial cancer?

P. H. Desai, P. Hughes, S. Edmee, N. Tchabo, D. H. Tobias, P. B. Heller and B. M. Slomovitz
Women's Cancer Center, Carol G Simon Cancer Center, Morristown, NJ

11:05 PM

322 - Poster Session A

Predicting model for lymph node metastasis using preoperative tumor grade, transvaginal ultrasound, and serum CA-125 level in patients with endometrial cancer

T. W. Kong¹, S. J. Chang¹, J. Paek¹ and H. S. Ryu²
¹Ajou University Hospital, Suwon, South Korea, ²Ajou University School of Medicine, Suwon, South Korea

11:25 PM

323 - Poster Session A

Outcomes in node-positive low-grade endometrioid endometrial carcinoma

C. St. Clair¹, R. Bhalla², K. Alektiar¹, M. L. Hensley², R. A. Soslow¹, Y. Sonoda¹, R. R. Barakat¹, N. R. Abu-Rustum¹ and M. M. Leitao¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Memorial Sloan-Kettering Cancer Center, New York, NY

11:45 PM

324 - Poster Session A

Age-adjusted Charlson comorbidity index is a prognostic factor in patients with early-stage uterine carcinoma: a study with 1,132 patients

M. Elshaikh, R. K. Hanna, M. Mahan and N. Rasool
Henry Ford Health System, Detroit, MI

12:05 AM

325 - Poster Session A

Nodal selection during side-specific lymphadenectomy in cases of failed sentinel node mapping

C. St. Clair¹, C. H. Kim², N. R. Abu-Rustum¹, M. M. Leitao¹, E. Jewell¹, G. J. Gardner¹, C. L. Brown¹, D. S. Chi¹, R. R. Barakat¹ and Y. Sonoda¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Thomas Jefferson University Hospital, Philadelphia, PA

12:25 AM

326 - Poster Session A

Taking it up a Notch: implications for outcomes in endometrial cancer

R. A. Previs, C. Ivan, H. J. Dalton, A. N. Davis, J. N. Bottsford-Miller, B. Zand, R. L. Coleman, K. A. Baggerly and A. K. Sood
The University of Texas MD Anderson Cancer Center, Houston, TX

12:45 AM

327 - Poster Session A

Prognostic factors of lymph node involvement in endometrioid endometrial cancer: a SEER analysis

R. Vargas¹, J. A. Rauh-Hain², J. T. Clemmer², R. M. Clark², A. Goodman², W. B. Growdon³, J. O. Schorge², M. G. Del Carmen², N. S. Horowitz⁴ and D. M. Boruta II²
¹Massachusetts General Hospital/Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital/Harvard University, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴Harvard University, Boston, MA

1:05 AM

328 - Poster Session A

Recurrence and survival in patients with uterine papillary serous carcinoma: do prior breast cancer and tamoxifen exposure influence outcomes?

S. R. Pierce¹, J. E. Stine¹, P. A. Gehrig¹, J. Nakayama², L. J. Havrilesky³, A. A. Secord³, A. C. Snavely¹, D. T. Moore¹ and K. H. Kim¹
¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of Virginia Health System, Charlottesville, VA, ³Duke University Medical Center, Durham, NC

1:25 AM

329 - Poster Session A

Expression of DNA repair proteins in endometrial cancer predicts disease outcome

C. M. Niemi¹, P. Mhawech-Fauceglia², S. Liu³ and T. Pejovic¹
¹Oregon Health & Science University, Portland, OR, ²University of Southern California, Los Angeles, CA, ³Roswell Park Cancer Institute, Buffalo, NY

1:45 AM

330 - Poster Session A

Lack of genomic predictors of recurrence in uterine carcinoma

J. G. Cohen¹, M. T. Goodman¹, B. Y. Karlan² and C. Walsh¹
¹Cedars-Sinai Medical Center, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA

2:05 AM

331 - Poster Session A

Genomic characterization of grade 3 endometrial carcinoma

J. G. Cohen¹, M. T. Goodman¹, B. Y. Karlan² and C. Walsh¹
¹Cedars-Sinai Medical Center, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA

2:25 AM

332 - Poster Session A

Efficacy of adjuvant therapy in women with stage IIIC2 endometrial cancer

G. Bogani, S. C. Dowdy, B. A. Cliby, J. N. Bakkum-Gamez, A. L. Weaver, B. S. Gostout, A. Jatoi, I. Petersen, K. C. Podratz and A. Mariani
Mayo Clinic, Rochester, MN

2:45 AM

333 - Poster Session A

Variations in practice for the management of high-risk histologic subtypes in endometrial cancer: a CHREC (Consortium of High Risk Endometrial Cancer) Canadian project

M. Q. Bernardini¹, L. T. Gien², G. Nelson³, S. Lau⁴, S. E. Ferguson¹, V. Samouelian⁵, A. Altman⁶, A. Cameron⁷, T. Ho⁸ and J. N. McAlpine⁹
¹Princess Margaret Hospital, Toronto, ON, Canada, ²Sunnybrook Odette Cancer Center, Toronto, ON, Canada, ³Tom Baker Cancer Centre, Calgary, AB, Canada, ⁴McGill University - Jewish General Hospital, Montreal, QC, Canada, ⁵Université de Montréal - Hopital Notre Dame, Montreal, QC, Canada, ⁶Winnipeg Health Sciences Centre, Winnipeg, MB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹University of British Columbia, Vancouver, BC, Canada

3:05 AM

334 - Poster Session A

Proteomic profiling of stage I endometrial cancers: a signature of early-stage recurrence in GOG 8016

N. P. Chappell¹, J. Mieznikowski², G. Wang³, B. L. Hood³, D. S. McMeekin⁴, C. A. Hamilton¹, T. P. Conrads³, G. L. Maxwell⁵, A. Wallace⁶, N. Ramirez⁷, L. Shepherd² and G. S. Rose⁸
¹Walter Reed National Military Medical Center, Bethesda, MD, ²Roswell Park Cancer Center, Buffalo, NY, ³Gynecologic Cancer Center of Excellence, Annandale, VA, ⁴The University of Oklahoma, Oklahoma City, OK, ⁵Inova Fairfax Hospital, Falls Church, VA, ⁶Duke University Medical Center, Durham, NC, ⁷Gynecologic Oncology Group Tissue Bank, Biopathology Center, Research Institute at Nationwide Children's Hospital, Columbus, OH, ⁸Mid Atlantic Pelvic Surgery Associates, Annandale, VA

3:25 AM

335 - Poster Session A

Combined modality adjuvant therapy for FIGO stage IIIC endometrial carcinomas

M. M. Leitao¹, J. A. Ducie¹, V. Makker², R. R. Barakat¹, C. Aghajanian¹, G. J. Gardner¹, K. Alektiar¹ and N. R. Abu-Rustum¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Memorial Sloan-Kettering Cancer Center, New York, NY

3:45 AM

336 - Poster Session A

Pelvic sentinel lymph node mapping and aortic nodal status in endometrial cancer: does infrarenal aortic lymph node metastasis really occur in isolation?

J. A. James, C. N. Jeppson, A. Gubbi, E. L. Takimoto, N. M. Stavitzski, S. Ahmad and R. W. Holloway
Florida Hospital Cancer Institute, Orlando, FL

4:05 AM

337 - Poster Session A

Proteomics of endometrial carcinogenesis: identification of candidates underlying disease pathogenesis

A. Alkhas¹, G. Wang², N. W. Bateman², C. A. Hamilton³, J. I. Risinger⁴, C. Zahn⁵, K. M. Darcy², G. L. Maxwell⁶, T. P. Conrads² and B. L. Hood²
¹Naval Medical Center San Diego, San Diego, CA, ²Gynecologic Cancer Center of Excellence, Annandale, VA, ³Walter Reed National Military Medical Center, Bethesda, MD, ⁴Michigan State University, Grand Rapids, MI, ⁵Uniformed Services University of the Health Sciences, Bethesda, MD, ⁶Inova Fairfax Hospital, Falls Church, VA

4:25 AM

338 - Poster Session A

Large tumors in endometrial cancer: a change in perspective

S. L. Yanke¹, M. M. K. Shahzad^1,2, R. J. Chappell¹ and D. M. Kushner¹
¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²H. Lee Moffitt Cancer Center, Tampa, FL

4:45 AM

339 - Poster Session A

Who should treat complex atypical endometrial hyperplasia?

A. B. Costales¹, K. M. Schmeler², R. Broaddus², P. T. Soliman², S. N. Westin², P. T. Ramirez² and M. Frumovitz²
¹The University of Texas Medical School at Houston, Houston, TX, ²The University of Texas MD Anderson Cancer Center, Houston, TX

5:05 AM

340 - Poster Session A

Is observation reasonable in older patients with early-stage uterine papillary serous carcinoma and clear cell carcinoma?

J. D. Boone, N. A. Nguyen, R. C. Arend, B. Smith, H. C. Machemehl, J. Fauci, M. Straughn, C. A. Leath III and K. S. Bevis
University of Alabama at Birmingham, Birmingham, AL

5:25 AM

341 - Poster Session A

Association between endometrioid endometrial cancer (EC) risk classification and gene expression in The Cancer Genome Atlas (TCGA) dataset

H. S. Chon, R. Abdallah, J. M. Lancaster, R. M. Wenham, S. M. Apte, P. L. Judson Lancaster, M. M. K. Shahzad and J. Gonzalez-Bosquet
H. Lee Moffitt Cancer Center, Tampa, FL

5:45 AM

342 - Poster Session A

Does the order of surgery and radiation therapy matter in the treatment of stage II endometrial cancer?

M. M. Boisen, J. F. Lin, A. B. Olawaiye, J. L. Kelley III, R. P. Edwards, J. T. Comerci and P. Sukumvanich
Magee-Womens Hospital of UPMC, Pittsburgh, PA

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

Poster Session A